Anti-Human IGF1 and IGF2 Recombinant Antibody (TAB-475CQ)

Customer Review

There are currently no Customer reviews or questions for TAB-475CQ. Click the button above to contact us or submit your feedback about this product.

Laura Scott
18.Oct,23

Excellent for Xentuzumab Research

The Xentuzumab has been excellent for our IGF-1R studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

David Young
05.Dec,22

Reliable in Multiple Assays

We incorporated this antibody into our Western blot and immunoassays, and it has been a great asset. The specificity for IGF-1R is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Megan Martinez
09.Jul,21

Consistent High-Quality Results

This antibody has proven to be consistent and high-quality in our various assays. The reproducible results and strong affinity for IGF-1R have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.

Q&As

1. Is the anti-IGF1 and IGF2 therapeutic antibody suitable for use in Western blotting?

   A: Yes, the anti-Xentuzumab therapeutic antibody (TAB-475CQ) is suitable for use in Western blotting. It provides specific binding to Xentuzumab, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-IGF1 and IGF2 therapeutic antibody?

   A: The recommended storage condition for the anti-Xentuzumab therapeutic antibody (TAB-475CQ) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-IGF1 and IGF2 therapeutic antibody be used in immunoprecipitation assays?

   A: Yes, the anti-Xentuzumab therapeutic antibody (TAB-475CQ) can be used in immunoprecipitation assays. It provides specific binding to Xentuzumab, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-IGF1 and IGF2 therapeutic antibody effective in ELISA applications?

   A: Yes, the anti-Xentuzumab therapeutic antibody (TAB-475CQ) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of Xentuzumab.

5. What is the optimal dilution for using the anti-IGF1 and IGF2 therapeutic antibody in immunofluorescence?

   A: The optimal dilution for using the anti-Xentuzumab therapeutic antibody (TAB-475CQ) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Hirsch, Theo Z., et al. "Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer." Cancer discovery 11.10 (2021): 2524-2543. https://doi.org/10.1158/2159-8290.CD-20-1809
   The study conducted an integrated genomic analysis of 126 pediatric liver tumors to uncover driver genes and mechanisms associated with cisplatin resistance. The research identified significant molecular heterogeneity in hepatoblastoma subtypes, revealing plasticity between different molecular subgroups such as "hepatocytic," "liver progenitor," and "mesenchymal." The study found that chemotherapy induces a specific mutational signature in "liver progenitor" cells, leading to heavily mutated relapses and metastases. Additionally, the research validated potential therapeutic targets for cisplatin-resistant progenitor cells through drug screening and mouse xenograft experiments.
   Creative Biolabs provided the monoclonal human anti-IGF1/IGF2 therapeutic antibody, Xentuzumab (Cat#: TAB-475CQ), which played a critical role in the study's investigation of new therapeutic strategies for pediatric liver cancer. The antibody was tested at a final concentration of 1 μmol/L, resuspended in PBS at 1 mg/mL, to evaluate its efficacy in inhibiting tumor growth. The provision of Xentuzumab by Creative Biolabs was essential in validating its potential as a targeted treatment, particularly for cisplatin-resistant progenitor cells, thereby contributing significantly to the exploration of alternative therapies for this aggressive form of cancer.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-475CQ, RRID: AB_3111962)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Xentuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Xentuzumab.

Related Diseases

Endocrine Resistance

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "IGF1 and IGF2"

Select a product category from the dropdown menu below to view related products.